Pancreatic cancer: a review of current treatment and novel therapies
HM Kolbeinsson, S Chandana, GP Wright… - Journal of Investigative …, 2023 - Taylor & Francis
Pancreatic cancer is one of the leading causes for cancer-related deaths in the United
States. Majority of patients present with unresectable or metastatic disease. For those that …
States. Majority of patients present with unresectable or metastatic disease. For those that …
[HTML][HTML] Carbohydrate antigen 19-9—Tumor marker: Past, present, and future
T Lee, TZJ Teng, VG Shelat - World journal of gastrointestinal …, 2020 - ncbi.nlm.nih.gov
Abstract Carbohydrate antigen 19-9 (CA 19-9) is a cell surface glycoprotein complex most
commonly associated with pancreatic ductal adenocarcinoma (PDAC). Koprowski first …
commonly associated with pancreatic ductal adenocarcinoma (PDAC). Koprowski first …
Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine/nab-paclitaxel for perioperative treatment of resectable …
SA Ahmad, M Duong, DPS Sohal, NS Gandhi… - Annals of …, 2020 - journals.lww.com
Objective: The optimal neoadjuvant therapy for resectable pancreatic ductal
adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods …
adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods …
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer
TF Stoop, RT Theijse, LWF Seelen… - Nature Reviews …, 2024 - nature.com
Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …
[HTML][HTML] Neoadjuvant treatment in pancreatic cancer
A Oba, F Ho, QR Bao, MH Al-Musawi… - Frontiers in …, 2020 - frontiersin.org
Thanks to the development of modern chemotherapeutic regimens, survival after surgery for
pancreatic ductal adenocarcinoma (PDAC) has improved and pancreatologists worldwide …
pancreatic ductal adenocarcinoma (PDAC) has improved and pancreatologists worldwide …
Response and survival associated with first-line FOLFIRINOX vs gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma
Importance Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) and
gemcitabine plus nanoparticle albumin-bound (nab)–paclitaxel (GA) are first-line …
gemcitabine plus nanoparticle albumin-bound (nab)–paclitaxel (GA) are first-line …
FDG-PET predicts neoadjuvant therapy response and survival in borderline resectable/locally advanced pancreatic adenocarcinoma
AM Abdelrahman, AH Goenka, R Alva-Ruiz… - Journal of the National …, 2022 - jnccn.org
Background: Neoadjuvant therapy (NAT) is used in borderline resectable/locally advanced
(BR/LA) pancreatic ductal adenocarcinoma (PDAC). Anatomic imaging (CT/MRI) poorly …
(BR/LA) pancreatic ductal adenocarcinoma (PDAC). Anatomic imaging (CT/MRI) poorly …
[HTML][HTML] Endoscopic ultrasound-guided biliary drainage of first intent with a lumen-apposing metal stent vs endoscopic retrograde cholangiopancreatography in …
Background & Aims Endoscopic ultrasound–guided choledochoduodenostomy with a lumen-
apposing metal stent (EUS-CDS) is a promising modality for management of malignant …
apposing metal stent (EUS-CDS) is a promising modality for management of malignant …
[HTML][HTML] State-of-the-art and upcoming innovations in pancreatic cancer care: a step forward to precision medicine
T Schepis, SS De Lucia, A Pellegrino, A Del Gaudio… - Cancers, 2023 - mdpi.com
Simple Summary Pancreatic cancer remains a major therapeutic challenge despite medical
advances. The incidence of pancreatic cancer is increasing, and this disease is associated …
advances. The incidence of pancreatic cancer is increasing, and this disease is associated …
Neoadjuvant FOLFIRINOX therapy is associated with increased effector T cells and reduced suppressor cells in patients with pancreatic cancer
H Peng, CA James, DR Cullinan, GD Hogg… - Clinical Cancer …, 2021 - AACR
Purpose: FOLFIRINOX has demonstrated promising results for patients with pancreatic
ductal adenocarcinoma (PDAC). Chemotherapy-induced immunogenic cell death can prime …
ductal adenocarcinoma (PDAC). Chemotherapy-induced immunogenic cell death can prime …